BiotechTube

Aflibercept (2.0 mg)

Phase 2Recruiting
0 views this week 0 watching💤 Quiet
Interest: 32/100
32
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Diabetic Macular Edema

Conditions

Diabetic Macular Edema

Trial Timeline

Mar 18, 2025 → Dec 1, 2027

NCT ID
NCT06942520

About Aflibercept (2.0 mg)

Aflibercept (2.0 mg) is a phase 2 stage product being developed by REGENXBIO for Diabetic Macular Edema. The current trial status is recruiting. This product is registered under clinical trial identifier NCT06942520. Target conditions include Diabetic Macular Edema.

What happened to similar drugs?

20 of 20 similar drugs in Diabetic Macular Edema were approved

Approved (20) Terminated (3) Active (0)
✅Pregabalin 150mg + Alpha-lipoic acid 480mg + Pregabalin 150mg + Alpha-Lipoic Acid 480mgYuhanApproved
✅Anplag(Sarpogrelate) + PlaceboYuhanApproved
✅Qutenza + PregabalinAstellas PharmaApproved
✅Duloxetine + Pregabalin + PlaceboShionogiApproved
✅duloxetine hydrochlorideEli LillyApproved
✅DuloxetineEli LillyApproved
✅duloxetine hydrochloride + pregabalin + gabapentinEli LillyApproved

Hype Score Breakdown

Clinical
12
Activity
15
Company
5
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT06942520Phase 2Recruiting

Competing Products

20 competing products in Diabetic Macular Edema

See all competitors
ProductCompanyStageHype Score
IVT aflibercept + Sham SC + SC CLS-TAClearside BiomedicalPhase 2
25
CHF6467 activeComac MedicalPhase 1/2
22
Ruboxistaurin mesylateEli LillyPhase 3
40
KVD001 InjectionKalVista PharmaceuticalsPhase 2
29
KVD001 InjectionKalVista PharmaceuticalsPhase 1
23
Baricitinib + PlaceboEli LillyPhase 2
35
LY3857210 + PlaceboEli LillyPhase 2
35
UBX1325Unity BiotechnologyPhase 2
25
Aflibercept + foselutoclaxUnity BiotechnologyPhase 2
25
UBX1325Unity BiotechnologyPhase 1
19
CT-P42 + EyleaCelltrionPhase 3
40
Pregabalin 150mg + Alpha-lipoic acid 480mg + Pregabalin 150mg + Alpha-Lipoic Acid 480mgYuhanApproved
43
Anplag(Sarpogrelate) + PlaceboYuhanApproved
43
CS-3150 + placeboDaiichi SankyoPhase 2
35
DS-5565 tablet + pregabalin capsule + Placebo tablet + placebo capsuleDaiichi SankyoPhase 2
35
olmesartan medoxomil + Placebo TabletsDaiichi SankyoPhase 3
40
DS-5565 + placeboDaiichi SankyoPhase 3
40
Mirogabalin + PlaceboDaiichi SankyoPhase 3
40
DS-5565Daiichi SankyoPhase 3
40
Beraprost sodiumAstellas PharmaPre-clinical
22